6 March 2023 Latest news on the development of a prophylactic treatment for FNAIT. NEW HAVEN, Conn.–(BUSINESS WIRE)–Mar. 6, 2023– Rallybio Corporation (Nasdaq: RLYB) today […]

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia     September 28, 2022 — […]

‘He’s never alone’ Dad has his head tattooed to honour his son’s brain surgery.     Carlos Marquez, from North Bergen, New Jersey, USA wanted to […]

Cambridge Rare Disease Network Festival #RAREfest22 – 25th-26th November 2022   RAREfest22 has patients at its heart with science and technology running through its veins! Cambridge […]

September 2021 New rules mean if you live in England your can now DONATE PLASMA!! Plasma is needed to make immunoglobulin medicine that can be used […]

  Rallybio Announces First-in-Human Dosing in RLYB211 Phase 1/2 Study. RLYB211 is in Clinical Development for the Prevention of FNAIT, a Potentially Life-Threatening Rare Disorder that […]

FREE to attend, RAREfest20 is a full day festival featuring interactive exhibits showcasing cool science, visionary technology and pioneering organisations, improving lives and bringing hope to […]

RAREfest20 A Global, virtual festival which puts rare diseases into the spotlight!   Despite the fact rare diseases affect one in seventeen people, those affected tell […]

  Severe thrombocytopenia leading to bleeding into major organs, including intracranial haemorrhage (ICH) can result in miscarriage, loss of the newborn or severe life-long neurological disability. […]